600422 logo

KPC Pharmaceuticals,Inc. Stock Price

SHSE:600422 Community·CN¥6.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

600422 Share Price Performance

CN¥8.93
-6.82 (-43.30%)
CN¥8.93
-6.82 (-43.30%)
Price CN¥8.93

600422 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate growth potential with mediocre balance sheet.

3 Risks
1 Reward

KPC Pharmaceuticals,Inc. Key Details

CN¥5.8b

Revenue

CN¥3.7b

Cost of Revenue

CN¥2.1b

Gross Profit

CN¥2.0b

Other Expenses

CN¥117.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.16
36.32%
2.03%
23.1%
View Full Analysis

About 600422

Founded
1951
Employees
5072
CEO
Jiang Zhong
WebsiteView website
www.kpc.com.cn

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. The company offers products in the field of cardiovascular and cerebrovascular, orthopedics series, antimalarial, gynecology, digestive system, and others treatments. It offers its products under Luotai, Tianxuanqing, Artemedine, Artem, and Arco brands. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals,Inc. was founded in 1951 and is based in Kunming, the People’s Republic of China.

Recent 600422 News & Updates

Recent updates

No updates